A new emerging target in cancer immunotherapy: Galectin-9 (LGALS9).
A new emerging target in cancer immunotherapy: Galectin-9 (LGALS9).
复制标题
DOI：
10.1016/j.gendis.2022.05.020
复制
发表时间：
2023-11
期刊：
影响因子：
6.8
通讯作者：
Feng, Jifeng
中科院分区：
文献类型：
--
作者：
Lv, Yan;Ma, Xiao;Ma, Yuxin;Du, Yuxin;Feng, Jifeng
在过去的几十年里，免疫学知识的进步导致了新的免疫检查点的发现，重新激活了癌症免疫治疗。以免疫检查点抑制剂为代表的免疫疗法已经成为癌症精准治疗的领跑者，为大多数癌症患者的治疗带来了新的曙光。半乳糖凝集素-9 （galectin -9, LGALS9）是一种广泛表达的蛋白，参与免疫调节和肿瘤发病，影响多种类型癌症的预后。半乳糖凝集素-9通过与其受体Tim-3的相互作用调节免疫稳态和肿瘤细胞存活。本文在简要介绍半乳糖凝集素-9和Tim-3的信号机制和免疫调节作用的基础上，综述了半乳糖凝集素-9在多种恶性肿瘤中的靶向表达模式，以及抗半乳糖凝集素-9治疗刺激抗肿瘤免疫反应的潜在机制。
Over the past few decades, advances in immunological knowledge have led to the identification of novel immune checkpoints, reinvigorating cancer immunotherapy. Immunotherapy, represented by immune checkpoint inhibitors, has become the leader in the precision treatment of cancer, bringing a new dawn to the treatment of most cancer patients. Galectin-9 (LGALS9), a member of the galectin family, is a widely expressed protein involved in immune regulation and tumor pathogenesis, and affects the prognosis of various types of cancer. Galectin-9 regulates immune homeostasis and tumor cell survival through its interaction with its receptor Tim-3. In the review, based on a brief description of the signaling mechanisms and immunomodulatory activities of galectin-9 and Tim-3, we summarize the targeted expression patterns of galectin-9 in a variety of malignancies and the promising mechanisms of anti-galectin-9 therapy in stimulating anti-tumor immune responses.
登录
查看更多内容
影响因子：
4.6
作者：
Baloche V;Rivière J;Tran TBT;Gelin A;Bawa O;Signolle N;Diop MBK;Dessen P;Beq S;David M;Busson P
通讯作者：
Busson P
影响因子：
3.7
作者：
Steichen AL;Simonson TJ;Salmon SL;Metzger DW;Mishra BB;Sharma J
通讯作者：
Sharma J
影响因子：
4.8
作者：
Chen, Zhifang;Dong, Di;Ding, Jianbing
通讯作者：
Ding, Jianbing
影响因子：
--
作者：
Chen, Hung-Lin;Liao, Fang;Liu, Fu-Tong
通讯作者：
Liu, Fu-Tong
Galectin-9在编程调节途径时将人B细胞桥接到血管内皮。
影响因子：
12.8
作者：
Chakraborty A;Staudinger C;King SL;Erickson FC;Lau LS;Bernasconi A;Luscinskas FW;Perlyn C;Dimitroff CJ
通讯作者：
Dimitroff CJ